Moomoo AIのまとめ
AbbVie reported Q3 2024 global net revenues of $14.5 billion, up 3.8% year-over-year, with operating earnings of $3.8 billion and diluted EPS of $0.88. Skyrizi revenues surged 50.8% to $3.2 billion and Rinvoq grew 45.3% to $1.6 billion, while Humira sales declined 37.2% to $2.2 billion due to biosimilar competition. The company completed strategic acquisitions of ImmunoGen and Cerevel Therapeutics during the quarter.The company's immunology portfolio showed strong momentum, with Skyrizi and Rinvoq demonstrating robust market share gains across all indications. Aesthetics revenue remained resilient with Botox Cosmetic growing 8.2% to $671 million, while neuroscience products like Vraylar and Botox Therapeutic delivered solid growth of 16.6% and 13.4% respectively. Operating margin improved significantly to 71% from 53% in the prior year.Looking ahead, AbbVie raised its quarterly dividend by 5.8% to $1.64 per share and maintained strong R&D investments across its pipeline. The company's cash flow from operations was $11.8 billion for the first nine months, while completing strategic acquisitions to strengthen its neuroscience and oncology portfolios. Management expects continued growth momentum from new products to offset Humira erosion.
AbbVie reported Q3 2024 global net revenues of $14.5 billion, up 3.8% year-over-year, with operating earnings of $3.8 billion and diluted EPS of $0.88. Skyrizi revenues surged 50.8% to $3.2 billion and Rinvoq grew 45.3% to $1.6 billion, while Humira sales declined 37.2% to $2.2 billion due to biosimilar competition. The company completed strategic acquisitions of ImmunoGen and Cerevel Therapeutics during the quarter.The company's immunology portfolio showed strong momentum, with Skyrizi and Rinvoq demonstrating robust market share gains across all indications. Aesthetics revenue remained resilient with Botox Cosmetic growing 8.2% to $671 million, while neuroscience products like Vraylar and Botox Therapeutic delivered solid growth of 16.6% and 13.4% respectively. Operating margin improved significantly to 71% from 53% in the prior year.Looking ahead, AbbVie raised its quarterly dividend by 5.8% to $1.64 per share and maintained strong R&D investments across its pipeline. The company's cash flow from operations was $11.8 billion for the first nine months, while completing strategic acquisitions to strengthen its neuroscience and oncology portfolios. Management expects continued growth momentum from new products to offset Humira erosion.
アッヴィは2024年第3四半期におけるグローバルな純売上高が145億ドルに達し、前年同期比で3.8%の増加を記録した。また、営業利益は38億ドル、希薄化後EPSは0.88ドルであった。Skyriziの売上は50.8%増の32億ドルに急増し、Rinvoqは45.3%増の16億ドルに成長したが、Humiraの売上はバイオシミラー競争により37.2%減の22億ドルとなった。同社は四半期中にイミュノジェンとセレベル・セラピューティクスの戦略的買収を完了した。同社の免疫学ポートフォリオは強い勢いを示しており、SkyriziとRinvoqは全ての適応症でロバストな市場シェアの増加を示している。美容関連の売...すべて展開
アッヴィは2024年第3四半期におけるグローバルな純売上高が145億ドルに達し、前年同期比で3.8%の増加を記録した。また、営業利益は38億ドル、希薄化後EPSは0.88ドルであった。Skyriziの売上は50.8%増の32億ドルに急増し、Rinvoqは45.3%増の16億ドルに成長したが、Humiraの売上はバイオシミラー競争により37.2%減の22億ドルとなった。同社は四半期中にイミュノジェンとセレベル・セラピューティクスの戦略的買収を完了した。同社の免疫学ポートフォリオは強い勢いを示しており、SkyriziとRinvoqは全ての適応症でロバストな市場シェアの増加を示している。美容関連の売上は堅調に推移し、ボトックス化粧品は8.2%増の67100万ドルとなった。一方、神経科学製品であるVraylarとボトックス治療薬はそれぞれ16.6%と13.4%の確固たる成長を記録した。営業利益率は前年の53%から71%に大幅に改善した。今後を見据えて、アッヴィは四半期配当を5.8%増の1.64ドルに引き上げ、パイプライン全体で強力なR&D投資を維持した。同社の営業からのキャッシュフローは最初の9ヶ月で118億ドルであり、神経科学および腫瘍学ポートフォリオを強化するための戦略的買収を完了した。経営陣はHumiraの減少を相殺するために新製品からの継続的な成長の勢いを期待している。
役に立った
役に立たない
